Drug record
What four public record sets show for bupropion. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | $0.070 each for the lowest-cost generic | Details |
| Medicare Part D, 2024 | $342.5 million | Details |
| FDA recall records | 44 | Details |
Whether the FDA lists this drug as in short supply.
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
The lowest-cost generic on file is Bupropion Hcl Sr 100 Mg Tablet: pharmacies pay about $0.070 each, or $2.11 for 30.
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| BUPROPION HCL 100 MG TABLET | Generic | $0.116 per each | $3.48 | Oct 21, 2026 |
| BUPROPION HCL 75 MG TABLET | Generic | $0.095 per each | $2.86 | Oct 21, 2026 |
| BUPROPION HCL SR 100 MG TABLET | Generic | $0.070 per each | $2.11 | Oct 21, 2026 |
| BUPROPION HCL SR 150 MG TABLET | Generic | $0.081 per each | $2.43 | Oct 21, 2026 |
| BUPROPION HCL SR 200 MG TABLET | Generic | $0.104 per each | $3.11 | Oct 21, 2026 |
| BUPROPION HCL XL 150 MG TABLET | Generic | $0.078 per each | $2.35 | Oct 21, 2026 |
| BUPROPION HCL XL 300 MG TABLET | Generic | $0.098 per each | $2.94 | Oct 21, 2026 |
| BUPROPION HCL XL 450 MG TABLET | Generic | $8.10 per each | $242.95 | Oct 21, 2026 |
| WELLBUTRIN SR 100 MG TABLET | Brand | $7.07 per each | $212.06 | Oct 21, 2026 |
| WELLBUTRIN SR 150 MG TABLET | Brand | $7.52 per each | $225.46 | Oct 21, 2026 |
| WELLBUTRIN SR 200 MG TABLET | Brand | $13.99 per each | $419.78 | Oct 21, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $342.5 million for the 7 products below. That is down 16% from $408.0 million in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Bupropion XL Bupropion HCl | $168.6 million | 1,486,328 | $24.68 | $113.45 | $222.3 million |
| Wellbutrin XL Bupropion HCl | $81.9 million | 3,395 | $4,390.39 | $24,121.90 | $74.0 million |
| Bupropion HCl SR Bupropion HCl | $46.0 million | 555,168 | $20.40 | $82.93 | $67.3 million |
| Aplenzin Bupropion HBr | $23.5 million | 831 | $5,004.44 | $28,304.31 | $14.1 million |
| Bupropion HCl Bupropion HCl | $17.0 million | 178,699 | $24.25 | $95.33 | $23.3 million |
| Wellbutrin SR Bupropion HCl | $5.2 million | 1,307 | $852.99 | $3,975.16 | $6.2 million |
| Forfivo XL Bupropion HCl | $236,682 | 97 | $666.71 | $2,440.02 | $781,850 |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year. Not counted here, combination products that contain it: Auvelity, Contrave.
Recalls reported to the FDA that name this drug.
The FDA has 44 recall records that name bupropion in the product description (9 Class II · 35 Class III). 3 are still marked ongoing.
Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India, Dist. by: Rising Phar, NDC 16571-863-03.
Reason: Failed Tablet/Capsule Specifications
buPROPion Hydrochloride Extended-release Tablets USP (XL) Once-Daily, 150 mg, 100 Tablets (10 x 10) per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC: 60687-782-01.
Reason: Failed Dissolution Specifications; the product is dissolving faster than the specified limits.
buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03
Reason: Presence of Foreign Tablets/Capsules
buPROPion Hydrochloride Extended-Release Tablets, USP (SR) 200 mg, 60 Tablets bottle, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Halol-Baroda Highway, Halol-389 350, Gujarat, India NDC 47335-738-86
Reason: Failed Dissolution Specifications
Bupropion Hydrochloride Extended-Release Tablets USP (SR), 150 mg, 60 tablets bottle, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 47335-737-86
Reason: Failed Dissolution Specifications
BuPROPion Hydrochloride Tablets, USP 75 mg, 100 Tablets (10 x 10) per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC carton: 60687-340-01; NDC Blister Pack: 60687-340-11
Reason: Failed Impurities/Degradation Specifications
buPROPion Hydrochloride Extended-Release Tablet, USP (SR), 200 mg, 60-count bottle, Rx only Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 47335-738-86
Reason: Presence Of Foreign Substance: Customer complaint for the presence of dark, gritty substance found within the bottle which was determined to be activated carbon from the desiccant canister inside the bottle.
buPROPion Hydrochloride Extended-Release Tablet, USP (SR), 150 mg packaged in a) 60-count bottle (47335-737-86), b)100-count bottle (47335-737-88), c)500-count bottle (47335-737-13), Rx only Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Halol-Baroda Highway, Halol-389 350, Gujarat, India
Reason: Presence Of Foreign Substance: Customer complaint for the presence of dark, gritty substance found within the bottle which was determined to be activated carbon from the desiccant canister inside the bottle.
bupropion Hydrochloride Tablets, USP 75 mg 100 Tablets Rx only NDC 23155-191-01 Manufactured for: Heritage Pharmaceuticals Inc. Eatontown, NJ 07724
Reason: CGMP Deviations: Intermittent exposure to temperature excursion during storage.
BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD
Reason: Failed Dissolution Specifications; 9-monthstability timepoint
Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99
Reason: Container packaging defect.
Bupropion Hydrochloride ER Tablets, USP 150 mg, packaged in a) 90-count bottle (NDC 69097-875-05), Manufactured for: Cipla USA Inc., 1560 Sawgrass Corporate Parkway, Suite 130 Sunrise, FL 33323 b) 90-count bottle (NDC 68001-322-05), For BluePoint Laboratories, Rx only, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788
Reason: Failed impurities/ degradation specifications: Out-of-specification results were observed in the meta-chlorobenzoic acid impurity in batches 18 months or older from date of manufacture in the 90 count bottle size.
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for bupropion. This page is public-record information, not medical advice.